{"id":503032,"date":"2021-06-11T08:33:22","date_gmt":"2021-06-11T12:33:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/"},"modified":"2021-06-11T08:33:22","modified_gmt":"2021-06-11T12:33:22","slug":"scynexis-to-present-at-the-bio-digital-international-convention-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/","title":{"rendered":"SCYNEXIS to Present at the BIO Digital International Convention 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <em>Company presentation will highlight BREXAFEMME<\/em><br \/>\n          <sup><br \/>\n            <em>\u00ae<\/em><br \/>\n          <\/sup><br \/>\n          <em> (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital setting<\/em>\n        <\/li>\n<\/ul>\n<p align=\"justify\">JERSEY CITY, N.J., June  11, 2021  (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (NASDAQ:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=i0ZuJbDmls3wSFg9FJsV2PQbuHqC1AJtjwVeg0alCo31Ai17FchBC2OTvuVsrtpGPUboYc5ebaX8Q-V6yri3pjvajcEO0rSjcOJ5OPLGKVW8ygpxiJPVoGjiwfE_1j8M\" rel=\"nofollow noopener\" target=\"_blank\">SCYX<\/a>), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present at the BIO Digital International Convention to be held virtually from June 10 \u2013 11 and 14 \u2013 18, 2021. The Company presentation will highlight BREXAFEMME<sup>\u00ae<\/sup> (ibrexafungerp tablets), in addition to other late-stage clinical trials evaluating ibrexafungerp in the community setting for recurrent vaginal yeast infections, and as a treatment for life threatening fungal infections, including <em>Candida auris,<\/em> in the hospital setting. The presentation is now available to registered attendees.<\/p>\n<p align=\"justify\">Attendees at BIO Digital will be able to view the SCYNEXIS Company Presentation before live meetings in the BIO One-on-One Partnering\u2122 system begin on June 14. To meet with the Company at BIO Digital, you can find registration information <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1pbj9c8gw_niUfqgdYH3VRLsDJ5W-4GV1zAnEOSP69wVEloaZmjdavb5yi9tCRE38W0QR3SofIjP--woaLZX28TdUHWK4-q6lqUFMnqe5kM=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0SCYNEXIS<\/strong>\n      <\/p>\n<p align=\"justify\">SCYNEXIS, Inc.\u00a0(NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. We are developing our lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. The New Drug Application (NDA) for BREXAFEMME<sup>\u00ae<\/sup>\u00a0(ibrexafungerp tablets) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ubU3kYAu4sVE2MBudaOKsrr2x86OIR-BteBhOVbrBrfUFlJVMc6wh2Nu6f41DbqiVtaYTvXH-_QpzD2o8J7Dkfodzilt_vMwfKRN_rzNlIs=\" rel=\"nofollow noopener\" target=\"_blank\">www.brexafemme.com<\/a>. We are also continuing late-stage clinical development of ibrexafungerp for the prevention of recurrent VVC as well as the treatment of life-threatening invasive fungal infections in hospitalized patients. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yC4lFEHw8Nrlme1iPod0ekpoNlhv7S-ptT936Y7nmMvuFVdum2Cml6Tz1MoMZVSutFoWerFCxgQQRr4yTK8AHQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.scynexis.com<\/a>.\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About BIO<\/strong>\n      <\/p>\n<p align=\"justify\">BIO is the world&#8217;s largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LQzZQu87XaFArPo_AXhCS25N2i8uwhWXvfeTN4mADkbhlyCS3ZJ29DfqP5T5jmfkNAujdD-nbgtspO3mER6EoiTpalUZKJ2sxBpMTSNhvluSauHQPx8Oj4Fpj30ARiIm\" rel=\"nofollow noopener\" target=\"_blank\">BIO International\u00a0Convention,<\/a>\u00a0the world\u2019s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=evUrgMMcJ0-Q249dtHfiYgCuf5xgb1kgxrutC-e_iRpso_40k9H_X_8v7xa9b0dghzx5kr28a-k2Rc3pe1Asn8ArtxRYfp2MLbtMyetHFPQ=\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe to Good Day BIO<\/a>.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>Irina Koffler<br \/>LifeSci Advisors<br \/>Tel: (646) 970-4681<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SUpMLtOjPIaPL2xOdBp7EJMk2oejsWMwWxUn_n9AjKsfxzv78P1pddaD4YOIFiWQWI69qmT1njdIc8tDJzMIvWZIJwPmkM4YMIUgZ692Vz7DXge4B0aLdFnLAnMJeZsA\" rel=\"nofollow noopener\" target=\"_blank\">ikoffler@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Relations<\/strong><br \/>\n        <br \/>Gloria Gasaatura<br \/>LifeSci Communications<br \/>Tel: (646) 970-4688<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2Sarp5dXbW7X0WBvkcBBiz99t-xx7-S7JR5bfT9u_t_dxEEP4i_HzYAbMtEf2MsoaPPE-cLQGkKPBV_3QSioM5k0xyY66FJCB2_VITnjKKGRNhw1ureKa8vS284VZdfy\" rel=\"nofollow noopener\" target=\"_blank\">ggasaatura@lifescicomms.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYwOCM0MjM3OTQ4IzUwMDA3MDcxOA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/7afeb562-5688-42d0-8ce1-673e299044ae\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company presentation will highlight BREXAFEMME \u00ae (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital setting JERSEY CITY, N.J., June 11, 2021 (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (NASDAQ:\u00a0SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present at the BIO Digital International Convention to be held virtually from June 10 \u2013 11 and 14 \u2013 18, 2021. The Company presentation will highlight BREXAFEMME\u00ae (ibrexafungerp tablets), in addition to other late-stage clinical trials evaluating ibrexafungerp in the community setting for recurrent vaginal yeast infections, and as a treatment for life &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SCYNEXIS to Present at the BIO Digital International Convention 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-503032","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SCYNEXIS to Present at the BIO Digital International Convention 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SCYNEXIS to Present at the BIO Digital International Convention 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company presentation will highlight BREXAFEMME \u00ae (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital setting JERSEY CITY, N.J., June 11, 2021 (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (NASDAQ:\u00a0SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present at the BIO Digital International Convention to be held virtually from June 10 \u2013 11 and 14 \u2013 18, 2021. The Company presentation will highlight BREXAFEMME\u00ae (ibrexafungerp tablets), in addition to other late-stage clinical trials evaluating ibrexafungerp in the community setting for recurrent vaginal yeast infections, and as a treatment for life &hellip; Continue reading &quot;SCYNEXIS to Present at the BIO Digital International Convention 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-11T12:33:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYwOCM0MjM3OTQ4IzUwMDA3MDcxOA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SCYNEXIS to Present at the BIO Digital International Convention 2021\",\"datePublished\":\"2021-06-11T12:33:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/\"},\"wordCount\":398,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjYwOCM0MjM3OTQ4IzUwMDA3MDcxOA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/\",\"name\":\"SCYNEXIS to Present at the BIO Digital International Convention 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjYwOCM0MjM3OTQ4IzUwMDA3MDcxOA==\",\"datePublished\":\"2021-06-11T12:33:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjYwOCM0MjM3OTQ4IzUwMDA3MDcxOA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjYwOCM0MjM3OTQ4IzUwMDA3MDcxOA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-present-at-the-bio-digital-international-convention-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SCYNEXIS to Present at the BIO Digital International Convention 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SCYNEXIS to Present at the BIO Digital International Convention 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/","og_locale":"en_US","og_type":"article","og_title":"SCYNEXIS to Present at the BIO Digital International Convention 2021 - Market Newsdesk","og_description":"Company presentation will highlight BREXAFEMME \u00ae (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital setting JERSEY CITY, N.J., June 11, 2021 (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (NASDAQ:\u00a0SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present at the BIO Digital International Convention to be held virtually from June 10 \u2013 11 and 14 \u2013 18, 2021. The Company presentation will highlight BREXAFEMME\u00ae (ibrexafungerp tablets), in addition to other late-stage clinical trials evaluating ibrexafungerp in the community setting for recurrent vaginal yeast infections, and as a treatment for life &hellip; Continue reading \"SCYNEXIS to Present at the BIO Digital International Convention 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-11T12:33:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYwOCM0MjM3OTQ4IzUwMDA3MDcxOA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SCYNEXIS to Present at the BIO Digital International Convention 2021","datePublished":"2021-06-11T12:33:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/"},"wordCount":398,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYwOCM0MjM3OTQ4IzUwMDA3MDcxOA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/","name":"SCYNEXIS to Present at the BIO Digital International Convention 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYwOCM0MjM3OTQ4IzUwMDA3MDcxOA==","datePublished":"2021-06-11T12:33:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYwOCM0MjM3OTQ4IzUwMDA3MDcxOA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjYwOCM0MjM3OTQ4IzUwMDA3MDcxOA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-present-at-the-bio-digital-international-convention-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SCYNEXIS to Present at the BIO Digital International Convention 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/503032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=503032"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/503032\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=503032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=503032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=503032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}